Cyclophosphamid

Phase 3Small molecule

EEssen Biotech

Cyclophosphamid is one of 334 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

333

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Germ Cell TumorCompleted

NeuroblastomaActive, not recruiting

Metastatic Colorectal CancerRecruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Germ Cell TumorPhase 2

Completed

NeuroblastomaPhase 3

Active, not recruiting

Metastatic Colorectal CancerPreclinical

Recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cyclophosphamid

EEssen Biotech

Phase 3

4 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Lexiscan

Astellas

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Recentin

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ANot yet recruiting

Diffuse Large B-Cell Lymphoma

NCT05990985

Q4 2026

Phase 1/2Recruiting

Esophageal Cancer

NCT06532799

Phase 1/2Recruiting

Breast Cancer

NCT06532812

Q2 2027

Phase 2Recruiting

Glomerulonephritis Rapidly Progressive

NCT06047171

Q3 2027

Phase 2/3Recruiting

Breast Cancer

NCT04576143

Clinical

Trials by Indication[1]

Breast Cancer4 trials

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Unknown status·SShanghai Pudong Hospital·N/A·NCT05656079·204 enrolled

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT04576143·260 enrolled

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532812·85 enrolled

Show 1 more trial

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Terminated·WWest German Study Group·Phase 2·NCT01690325·21 enrolled

Acute Myeloid Leukemia3 trials

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05601466·3 enrolled

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Unknown status·ZZhejiang University·Phase 1·NCT05665075·19 enrolled

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05987696·2 enrolled

B-cell Malignancies1 trial

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Unknown status·ZZhejiang University·Phase 1·NCT05379647·24 enrolled

Conditioning1 trial

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Not yet recruiting·—·Phase 2·NCT06238245·22 enrolled

Ovarian Cancer1 trial

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated·IInge Marie Svane·Phase 1/2·NCT04611126·6 enrolled

15 more indications

Neuroblastoma1 trial

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Cell Therapy1 trial

Natural Killer(NK) Cell Therapy in r/r AML

Unknown status·ZZhejiang University·Phase 1·NCT05665114·18 enrolled

Myeloid Malignancies1 trial

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Completed·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT04943757·50 enrolled

Pancreatic Cancer1 trial

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Unknown status·MMoscow Clinical Scientific Center··NCT05580887·35 enrolled

Esophageal Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532799·75 enrolled

Diffuse Large B-Cell Lymphoma1 trial

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruiting·TThe First Hospital of Jilin University·N/A·NCT05990985·20 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Not yet recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT07493538·132 enrolled

Lupus Nephritis1 trial

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Unknown status·—·Phase 3·NCT05432531·60 enrolled

Multiple Myeloma1 trial

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04706936·25 enrolled

Prevention1 trial

ATG Plus Low-dose PT-Cy for GVHD Prevention

Terminated·PPeking University People's Hospital·Phase 3·NCT06108739·66 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Recruiting·UUniversity of Liege·Phase 2·NCT03852407·114 enrolled

Minimal Residual Disease1 trial

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05601830·1 enrolled

Glomerulonephritis Rapidly Progressive1 trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Germ Cell Tumor1 trial

Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05634785·2 enrolled

Metastatic Colorectal Cancer1 trial

A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer

Recruiting·CCuracell Holding AB·Preclinical·NCT07255664·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Cyclophosphamid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Essen Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEssen Biotech

Cyclophosphamid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Breast Cancer4 trials

Acute Myeloid Leukemia3 trials

B-cell Malignancies1 trial

Conditioning1 trial

Ovarian Cancer1 trial

Neuroblastoma1 trial

Cell Therapy1 trial

Myeloid Malignancies1 trial

Pancreatic Cancer1 trial

Esophageal Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Lupus Nephritis1 trial

Multiple Myeloma1 trial

Prevention1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Minimal Residual Disease1 trial

Glomerulonephritis Rapidly Progressive1 trial

Germ Cell Tumor1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News